FOLH1 and pachyonychia congenita: Radiolabeled 68Ga-PSMA-11 and 18F-DCFPyL were approved by the FDA in 2020 and 2021 for PC patients at high risk for pelvic nodal metastases and biochemical recurrent prostate cancer (Eder et al., 2012).